LUPIN LABS POSTS 41% INCREASE IN NET PROFIT
Article Abstract:
Lupin Laboratories has recorded 41 percent increase in net profit and eight percent rise in sales for the financial year ended June 30, 1998. --------------------------------------------------------- Lupin Laboratories: Financial Results (Rs in crore) --------------------------------------------------------- Particulars 1997-98 1996-97 --------------------------------------------------------- Sales 695 642 --------------------------------------------------------- Exports 200 230 --------------------------------------------------------- Interest 47 43 --------------------------------------------------------- Depreciation 12 11 --------------------------------------------------------- Taxation 2 1.5 --------------------------------------------------------- Earning per share (Rs) 11 7.8 --------------------------------------------------------- Lupin launched 15 new brands in 1997-98. It also reduced the percentage of its turnover of drugs covered by price control from 46 percent to 44 percent. The exports declined mainly due to a 20 percent fall in international prices of cefalexin and ceftriaxone. (gsh)
Comment:
Posts sales of Rs695 crore in 1997-98 compared to Rs642 crore in 1996-97
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
LUPIN TO BUY US CO FOR $35 M
Article Abstract:
The Rs642 crore Lupin Laboratories plans to acquire the assets and businesses of an US firm at a cost of $30-35 million. The FDA approved US company manufactures formulations of Cephalosporins and has sales of $100 million. This acquisition will enable Lupin to export its Cephalosporin bulk drug to USA and manufacture formulations for the US market. Lupin plans to file abbreviated new drug applications to sell generic Cephalosporins in the US market. The acquisition will increase the company's profit and sales in 1998-99. (gsh)
Comment:
Plans to acquire assets and businesses of a US firm at a cost of $30-35 mil
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
LUPIN LABS PLANS THREE MORE ACQUISITIONS IN CHINA, US, EU
Article Abstract:
Lupin Laboratories is likely to acquire three companies in China, US and European Union by June 1999. It plans to invest over $10 million in these acquisitions. The acquisitions in US and Europe will focus on products other than cephalosporins. The company has designated consultants to evaluate a formulation unit in China, which it intends to acquire. It plans to launch three products, cefotaxime, cefalexin and cefachlor in US and anticipates a profit of $5 million from each of these products per year. (um)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: ASIAN PAINTS POSTS 22% RISE IN NET ICI PAINTS ROSY PICTURE WITH 20% RISE IN NET
- Abstracts: BALRAMPUR CHINI MILLS LIMITED BALRAMPUR CHINI ON ACQUISITION PROWL AGAIN. BALRAM CHINI TO RESTRUCTURE EQUITY CAPITAL
- Abstracts: BPCL REGISTERS 23% RISE IN NET BPCL H1 NET SALES UP. BPCL TO EXPAND CAPACITY TO 10 M TONNES
- Abstracts: SMITHKLINE BEECHAM PHARMACEUTICALS - A SPURT FROM THE STARTING BLOCKS SMITHKLINE BEECHAM PHARMACEUTICALS
- Abstracts: $220-M GERMAN BANK LOAN FOR MAHESHWAR HYDEL PROJECT S KUMARS' HYDEL PROJECT REACHES FINANCIAL CLOSURE KPCL SEEKS Rs200-CR LOAN FROM VA TECH